Form S-3ASR 4D Molecular Therapeutic
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Form S-3ASR 4D Molecular Therapeutic
February 7, 2024 4:53 AM EST
(Updated - February 7, 2024 5:21 AM EST)
Goldman Sachs analyst Salveen Richter reinstates coverage on 4D Molecular Therapeutics (NASDAQ: FDMT) with a Buy rating and a price target of $81.00.
The analyst comments "Given positive Ph2 intravitreal gene therapy 4D-150 data in wet age-related macular degeneration (wAMD), and the planned Ph3 initiation in 1Q25, we move from Not... More
February 5, 2024 4:38 PM EST
4D Molecular Therapeutics Inc. (NASDAQ: FDMT) has filed mixed shelf of:
Common Stock
Preferred Stock
Debt Securities
Warrants
Units
...
More
February 5, 2024 4:38 PM EST
4D Molecular Therapeutics Inc. (NASDAQ: FDMT) has filed mixed shelf of:
Common Stock
Preferred Stock
Debt Securities
Warrants
Units
...
More
